Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: The Top Last-Minute Movers of 2021

Expecting the markets to be relaxed heading into the holidays? Hardly. Many investors and brokers know that this is the time to shine. With every twist and turn the global economy has been throwing our way, the right move is staying active. This past week, it seems ma...
Stockhouse Editorial | December 7, 2021 |

Bringing Hope to People Living with Neurodegenerative Diseases

Alpha Cognition Inc. ( TSX-V.ACOG , OTCMKTS: ACOGF , Forum ) is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases. Stockhouse Media’s Dave Jackson caught up recently with Company CE...
Dave Jackson | October 20, 2021 |

A Battery Materials Company Helping Fuel Europe’s EV Revolution

(Click image above to play video) Stockhouse investors know there is no denying the fact that the world’s industrial and economic future will be closely tied to lithium-ion batteries and the battery metals needed to build them. But what a lot...
Dave Jackson | March 23, 2021 |

One of the Best Valued Companies in the Digital Assets Space

(Click image to play video) The booming financial technology, or fintech, sector is currently one of the hottest and most risk-adverse in capital markets today. And one Canada-based company is gaining significant traction and investor interest in this cutting-ed...
Dave Jackson | March 23, 2021 |

A Splendid Investment Opportunity…Naturally

(Click image to play video) We’re just about smackdab in the middle of New Year’s resolution time, and millions of North Americans are committing to a healthier lifestyle or just trying to shed a few pounds. Coquitlam, BC-based...
Dave Jackson | January 22, 2021 |

Where Today’s Leading-Edge Technology Meets a Historical Gold Mine

When Stockhouse Editorial last caught up with Ron Coombes , the President, Chief Executive Officer and Director of Providence Gold Mines Inc. (PHD) ( TSX-V.PHD , OTC: PRRVF , Forum ), he mentioned that a top geologist once told him the simple but wise words, “Gold is...
Dave Jackson | December 4, 2020 |

Analyst: G1 Minimizes the Carnage of Chemotherapy

ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. In a June 26 research note, analyst Tony Butler reported that ROTH Capital Partners initiated coverage on G1 Therapeutics Inc. (GTHX:NASDAQ) with a Buy ...
Streetwise Reports | July 2, 2020 |

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug

Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report. In a June 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that the U.S. Food and Drug Administration (FDA) designated Axsome Therapeutics...
Streetwise Reports | July 2, 2020 |

Is the Stock Bulls' Cup Half-Full or Half-Empty?

Neither on Monday, nor on Tuesday did we see strong volume, but prices rose regardless –is it time to bet the farm on higher stocks right next? As quite a few yesterday-mentioned reasons to be cautious were resolved bullishly, the buyers' case got stronger. S&P 500 in the ...
Monica Kingsley | June 4, 2020 |

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. In a May 26 research note, ROTH Capital Partners analyst Tony Butler purported that Atara Biotherapeutics Inc.'s (ATRA:NASDAQ) "updated data from the Phase 1 ...
Streetwise Reports | May 28, 2020 |
1 2 3 4 5